Leukemia clinical trials in Texas
31 studies for Leukemia are looking for participants at sites in Texas.
Cities in Texas
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
- Quetzal Site 6, Houston
RecruitingPhase 3
Ages 18 to 71 · All sexes · Updated Sep 23, 2026 · NCT07504458Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
- M D Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 1 to 25 · All sexes · Updated Sep 23, 2026 · NCT05645718Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
- Texas Children's Hospital, Houston
- The Methodist Hospital, Houston
RecruitingPhase 1
Up to age 75 · All sexes · Updated Sep 16, 2026 · NCT06345027Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
- The Methodist Hospital Research Institute, Houston
- The University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT06824168(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- The University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT04996875A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
- MD Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Sep 11, 2026 · NCT06229912Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Houston
RecruitingPhase 3
Ages 18 to 18 · All sexes · Updated Sep 8, 2026 · NCT07509151First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
- Cook Children's Medical Center, Fort Worth
- Texas Children's Hospital, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 1, 2026 · NCT07586618Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
- MD Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07284433Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
- MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT06001788Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Texas Oncology-Austin Midtown, Austin
- Texas Oncology-Presbyterian Cancer Center, Dallas
- University of Texas, Houston
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT07007312AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
- Research Site, Houston
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Aug 19, 2026 · NCT06137118Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- University of Texas, Southwestern, Dallas
- Baylor Texas Children's Hospital, Houston
RecruitingPhase 2
Ages 7 to 25 · All sexes · Updated Aug 19, 2026 · NCT05082519Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Aug 6, 2026 · NCT06533579Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
- University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 60 and older · All sexes · Updated Jul 16, 2026 · NCT01515527CD4CAR for CD4+ Leukemia and Lymphoma
- The University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 12 and older · All sexes · Updated Jun 24, 2026 · NCT03829540A Study of Revumenib and Mezigdomide in People With Leukemia
- MD Anderson Cancer Center (Data Collection Only), Houston
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Jun 22, 2026 · NCT07356154A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
- Dren Investigational Site, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 17, 2026 · NCT05475925Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Texas Children's Hospital, Houston
RecruitingObservational study
Ages 0 to 38 · All sexes · Updated Jun 4, 2026 · NCT06131801Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
- M D Anderson Cancer Center, Houston
RecruitingObservational study
Ages 18 and older · All sexes · Updated May 20, 2026 · NCT05011045Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- University of Texas Health Science Center at San Antonio, San Antonio
RecruitingObservational study
All ages · All sexes · Updated May 18, 2026 · NCT01790152Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
- M D Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 30, 2026 · NCT05536349A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- University of Texas Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Apr 30, 2026 · NCT04256317The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- University of Texas(UT) Southwestern-Children's Medical Center, Dallas
RecruitingPhase 1/2
Ages 12 to 95 · All sexes · Updated Apr 15, 2026 · NCT04329728A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Sarah Cannon Research Institute - St. David's South Austin Medical Center / Texas Oncology South Austin, Austin
- UT Southwestern - Simmons Cancer Center, Dallas
- MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 13, 2026 · NCT05735184Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
- Mays Cancer Center at UT Health San Antonio, San Antonio
Recruiting
Ages 18 and older · All sexes · Updated Feb 20, 2026 · NCT05745285cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Elligo Health Research, Inc., Austin
RecruitingObservational studyHealthy volunteers welcome
Ages 40 and older · All sexes · Updated Jan 20, 2026 · NCT05366881Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
- The University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 31, 2025 · NCT06549790SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Dallas
- Massive Bio SYNERGY-AI site, Houston
- Massive Bio SYNERGY-AI site, Temple
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
- The University of Texas M.D. Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 24, 2025 · NCT06501196Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 15, 2024 · NCT06034275From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.